Question: Alectinib developed by Hoffmann-La Roche is used to treat which type of cancer?
Context: André S. Dreiding (22 June 1919 in Zürich – 24 December 2013 in Herrliberg near Zurich) was a Swiss chemist.  He finished his high school studies in Zürich and then studied at Columbia University in New York where he was awarded BS and MS degrees.  After two years as research assistant at Hoffmann-La Roche, he continued postgraduate studies at University of Michigan in Ann Arbor under professor Werner Emmanuel Bachmann, and was awarded his Ph.D. in 1947.  He remained at the university until 1949 as Rackham and Lloyd Postdoctoral Fellow.  From 1949 to 1954, Dreiding was assistant professor at Wayne University, Detroit Institute of Cancer Research.  He also temporarily took over Bachmann's teaching and research duties at the University of Michigan after Bachmann's death in 1951, and held them until 1952.  In 1954, Dreiding turned to Switzerland and University of Zurich, where he became professor, and stayed until his retirement in 1987, after which he has been emeritus professor. Befetupitant (Ro67-5930) is a drug developed by Hoffmann-La Roche which acts as a potent and selective antagonist for the NK receptor.  It was originally developed as a potential antiemetic drug, though development was ultimately discontinued after a related drug netupitant was deemed to be more suitable for clinical development.  Befetupitant has however continued to be researched for other possible applications such as treatment of corneal neovascularization. Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC).  It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.  Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.  The company headquarters are located in Basel. EPPTB (RO-5212773) is a drug developed by Hoffmann-La Roche which acts as a potent and selective inverse agonist of trace amine-associated receptor 1 (TAAR1), with no significant activity at other targets.  EPPTB is one of the first selective antagonists developed for TAAR1, and has been used to demonstrate an important role for TAAR1 in regulation of dopaminergic signalling in the limbic system.  Unfortunately while EPPTB has high affinity for the mouse TAAR1, it has much lower affinity for rat and human TAAR1, which limits its use in research.  While the human and mouse forms of TAAR1 have similar functions and bind similar ligands, the actual binding affinities of individual ligands often vary significantly between the two versions of the receptor. Apronal (brand name Sedormid), or apronalide, also known as allylisopropylacetylurea or allylisopropylacetylcarbamide, is a hypnotic/sedative drug of the ureide (acylurea) group synthesized in 1926 by Hoffmann-La Roche that is no longer used, but only used in Japan (See ).  Though it is not a barbiturate, apronalide is similar in structure to the barbiturates (being an open-chain carbamide instead of having a heterocyclic ring).  In accordance, it is similar in action to the barbiturates, although considerably milder in comparison (formerly used as a daytime sedative at doses of 1 to 2 grams every 3 to 4 hours).  Upon the finding that it caused patients to develop thrombocytopenic purpura, apronalide was withdrawn from clinical use. Bumetanide (trade names Bumex or Burinex) is a loop diuretic of the sulfamyl category, most often used to treat heart failure.  It is often used in people in whom high doses of furosemide or other diuretics are ineffective.  It is marketed by Hoffmann-La Roche.  The main difference between bumetanide and furosemide is in their bioavailability and potency.  About 60% of furosemide is absorbed in the intestine, and there are substantial inter- and intraindividual differences in bioavailability (range 10-90%).  About 80% of bumetanide is absorbed, and its absorption does not change when it is taken with food.  It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Fritz Hoffmann, later Fritz Hoffmann-La Roche (24 October 1868, Basel (French: "Bâle" ) 18 April 1920, Basel) was the founder of Hoffmann-La Roche Ltd. (French: "F. Hoffmann-La Roche SA" , German: "die F. Hoffmann-La Roche AG" ). Roche Diagnostics is a diagnostic division of Hoffmann-La Roche which manufactures equipment and reagents for research and medical diagnostic applications.  Internally, it is organized into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana).  The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland. Clomethiazole (also called chlormethiazole) is a sedative and hypnotic originally developed by Hoffmann-La Roche in the 1930s.  The drug is used in treating and preventing symptoms of acute alcohol withdrawal.
Answer: non-small-cell lung cancer